Halozyme Therapeutics, Inc. (HALO) Stock
Key stats
- Market cap
- $11.59B
- Price / Earnings ratio
- 24.2x
- EPS (TTM)
- $4.24
- Volume
- Loading
- 52-week high
- $134.00
- 52-week low
- $61.23
Source: third-party data provider, as of November 13, 2026
Compare with HALO
Recent news

HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
HALO

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
HALO

Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth
Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth
HALO

5 Strong Buy Growth Stocks With High Margins to Grab Before Earnings
5 Strong Buy Growth Stocks With High Margins to Grab Before Earnings
HALO
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 27.80
- MACD 12/26/9
- -2.09
- EMA 9 of MACD
- 1.70
- MACD histogram
- -3.79
- SMA 50
- $114.95
- Price below SMA 50
- EMA 50
- $113.46
- Price below EMA 50
- SMA 200
- $85.15
- Price above SMA 200
- EMA 200
- $90.21
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $1.86 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
HALO

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
HALO

Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth
Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth
HALO

5 Strong Buy Growth Stocks With High Margins to Grab Before Earnings
5 Strong Buy Growth Stocks With High Margins to Grab Before Earnings
HALO

Halozyme's Strong Earnings Growth Sends Shares Higher
Halozyme's Strong Earnings Growth Sends Shares Higher
HALO

5 Stocks to Buy Using the Relative Price Strength Strategy
5 Stocks to Buy Using the Relative Price Strength Strategy
HALO

Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains
Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains
HALO

3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
HALO

Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
HALO

Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?
Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?
HALO
News tone: automated (AI) classification of the article's content, not a price prediction.
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. | President, CEO & Director | 1963 |
| Mr. Darren Snellgrove | Senior VP & CFO | — |
| Mr. Mark Snyder Esq. | Executive VP, General Counsel, Chief Compliance Officer & Corporate Secretary | 1967 |
| Mr. Brian Sweeney | Chief Human Resources Officer | 1964 |
| Mr. David A. Ramsay MBA | President of Drug Delivery | 1965 |
| Dr. Christopher Wahl M.B.A., M.D. | Chief Scientific Officer | — |
| Dr. Charles P. Theuer M.D., Ph.D. | Chief Medical Officer | 1964 |
| Mr. Paul Spence | Chief Commercial Officer | 1969 |
| Mr. Rhys de Callier | Chief Strategy Officer | — |
| Mr. Chase Coffman Ph.D. | President of Hypercon | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 27.80
- MACD 12/26/9
- -2.09
- EMA 9 of MACD
- 1.70
- MACD histogram
- -3.79
- SMA 50
- $114.95
- Price below SMA 50
- EMA 50
- $113.46
- Price below EMA 50
- SMA 200
- $85.15
- Price above SMA 200
- EMA 200
- $90.21
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $79.00
- Average
- $118.63
- High
- $149.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -13.9 | +25.0 | ||||||||||
| 2022 | -15.7 | +0.9 | +11.9 | -4.1 | +12.6 | -3.1 | +9.9 | -16.1 | -2.6 | +19.3 | +18.6 | -0.9 |
| 2023 | -6.1 | -8.0 | -19.8 | -17.1 | -0.6 | +11.0 | +16.5 | +0.7 | -10.8 | -10.1 | +15.2 | -6.9 |
| 2024 | -9.5 | +16.2 | -1.0 | -7.8 | +12.7 | +16.2 | +6.2 | +16.0 | -6.5 | -10.7 | -15.7 | -1.6 |
| 2025 | +18.0 | +5.1 | +10.1 | -0.7 | -6.6 | -6.5 | +13.3 | +23.9 | +0.0 | -13.0 | +7.9 | -1.2 |
| 2026 | +2.0 | -6.6 | -7.5 | -2.7 | +4.0 | +14.9 | +7.2 | +29.4 | +2.5 | +22.4 | -21.1 |



